Assessing contrast sensitivity change in retinal diseases with use of yellow-amber NoIR glasses

使用黄琥珀色NoIR眼镜评估视网膜疾病的对比敏感度变化

阅读:1

Abstract

PURPOSE: The purpose of this study was to assess change of contrast sensitivity (CS) in subjects having retinal diseases with yellow-amber no infrared (NoIR) glasses used as low vision aid (LVA). METHODS: We examined CS in 82 low vision (LV) subjects having retinal diseases with Pelli Robson Chart at 1 m distance before and after wearing yellow-amber NoIR glasses. We also found type of retinal affection and macular optical coherence tomography (OCT) features. RESULTS: The distance and near best-corrected visual acuity (BCVA) was, respectively, 0.68 ± 0.17 (median = 0.70) and 0.72 ± 0.25 (median = 0.70) logmar units. The pre-LVA CS was 0.52 ± 0.29 (median = 0.3) and post- LVA was 0.52 ± 0.28 (median = 0.45) logunits (mean reduction = -0.002 ± 0.24; Median reduction = 0; P = 0.909). The pre-LVA and post-LVA CS showed a negative correlation with logmar distance BCVA [r = -0.090; P = 0.317 and r = -0.152; P = 0.090 respectively]. The pre-LVA and post-LVA CS showed a negative correlation with logmar near BCVA [r = -0.114; P = 0.207 and r = -0.054; P = 0.549 respectively]. The CS did not improve in subjects having macular degeneration, pathological myopia, hereditary maculopathy, and diabetic retinopathy. The macular OCT features like fluid, exudates, scars, drusens, traction, and hole did not significantly influence CS both at pre-LVA and post-LVA stage. CONCLUSION: This is the first study with yellow-amber NoIR glasses which blocks "both ultraviolet and infrared light." The subjects having macular degeneration, pathological myopia, hereditary maculopathy, and diabetic retinopathy did not improve in CS with filters. The correlation values showed that filters may improve CS in subjects having good baseline BCVA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。